- Home
- GF vs ENLV Comparison
GF vs ENLV Comparison
Compare GF & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GF | ENLV |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | Germany | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.2M | 196.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GF | ENLV |
|---|---|---|
| Price | $11.59 | $0.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 55.0K | ★ 409.3K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.66 |
| 52 Week High | $12.82 | $2.10 |
Technical Indicators
Market Signals| Indicator | GF | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 39.07 |
| Support Level | $11.23 | $0.66 |
| Resistance Level | $11.71 | $1.23 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 35.00 | 6.44 |
Price Performance
Historical ComparisonAbout GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investments includes investments in different sectors such as the industrials, information technology, materials, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.